Inhibitors of ASAH1 have demonstrated efficacy in preclinical studies, reducing tumor cell growth and potentially overcoming resistance to standard treatments such as TMZ.302 While no clinical trials currently focus on ceramide signaling in GBM, further research into ASAH1 inhibition could provide novel approaches to restoring ceramide-induced apoptosis and improving patient outcomes. Here, ASAH1 is linked to glioblastoma.